News

December 15, 2009

Alethia Biotherapeutics announces the nomination of Dr. Michael Berendt to the Board of Directors

December 7, 2009

Alethia Biotherapeutics in-licenses a peptide for imaging of solid tumors in vivo and announces positive pre-clinical results of AB-16B5 in prostate and breast cancer

November 30, 2009

Alethia Biotherapeutics collaborators at the NRC-BRI publish results in Oncogene on the role of secreted clusterin as an important mediator of EMT

May 26, 2009

Alethia Biotherapeutics extends its collaborative agreement with Biosite for monoclonal antibody development

May 6, 2009

Alethia Biotherapeutics exercises its option to license Clusterin-specific antibodies for cancer therapeutics and diagnostics with National Research Council Canada’s Biotechnology Research Institute (NRC-BRI)

April 23, 2009

Alethia Biotherapeutics announces the closing of a $2.2 M financing

More news

Events

February 28 - March 2, 2010

AACR Special Conference on EMT and Cancer Progression and Treatment - Westin Arlington Gateway Hotel in Arlington, Virginia, USA

Mario Filion and Gilles Tremblay will be in attendance.

March 8-10, 2010

BIO-Europe Spring - Barcelona, Spain

Yves Cornellier and Mario Filion will be in attendance.

April 17-21, 2010

Alethia Biotherapeutics to present at  the AACR 101st Annual Meeting 2010 in Washington, DC, USA

AB-16B5, a therapeutic monoclonal antibody against human clusterin that blocks the epithelial-to-mesenchymal transition - Tumor Biology 16, Monday April 19, 2010 9:00 AM - 12:00 PM, Exhibit Hall A-C, Poster Section 18

Mario Filion and Gilles Tremblay will be in attendance.

May 3-6, 2010

Alethia Biotherapeutics to be part of the 2010 BIO International Convention - Chicago, IL, USA

Yves Cornellier and Mario Filion will be in attendance.